Dehydroepiandrosterone-dependent induction of peroxisomal proliferation can be reduced by aspartyl esterification without attenuation of inhibitory bone loss in ovariectomy animal model.
The purpose of this study was to determine whether esterification of dehydroepiandrosterone with aspartate (DHEA-aspartate) could reduce peroxisomal proliferation induced by DHEA itself, without loss of antiosteoporotic activity. Female Sprague-Dawley rats were ovariectomized, then DHEA or DHEA-aspartate was administered intraperitoneally at 0.34 mmol/kg BW 3 times a week for 8 weeks. DHEA-aspartate treatment in ovariectomized rats significantly increased trabeculae area in tibia as much as DHEA treatment. Urinary Ca excretion was not significantly increased by DHEA or DHEA-aspartate treatment in ovariectomized rats, while it was significantly increased by ovariectomy. Osteocalcin concentration and alkaline phosphatase activity in serum and cross linked N-telopeptide type I collagen level in urine were not significantly different between DHEA-aspartate and DHEA treated groups. DHEA-aspartate treatment significantly reduced liver weight and hepatic palmitoyl-coA oxidase activity compared to DHEA treatment. DHEA-aspartate treatment maintained a nearly normal morphology of peroxisomes, while DHEA treatment increased the number and size of peroxisomes in the liver. According to these results, it is concluded that DHEA-aspartate ester has an inhibitory effect on bone loss in ovariectomized rats with a marked reduction of hepatomegaly and peroxisomal proliferation compared to DHEA.
Kwak
C S
CS
Aging and Physical Culture Research Institute, Seoul National University, Korea. kwakcs@snu.ac.kr
Kang
C M
CM
Kang
H S
HS
Song
K Y
KY
Lee
M S
MS
Seong
S C
SC
Park
S C
SC
D042964:Acyl-CoA Dehydrogenase; D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001224:Aspartic Acid / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D015415:Biomarkers; D002118:Calcium / Q000097:blood / Q000652:urine; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003687:Dehydroepiandrosterone / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D004195:Disease Models, Animal; D004951:Esterification; D044943:Fatty Acid Desaturases / Q000378:metabolism; D005260:Female; D007274:Injections, Intraperitoneal; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D009929:Organ Size; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D010052:Ovariectomy; D020675:Peroxisomes / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000378:metabolism / Q000473:pathology; D014280:Triglycerides / Q000097:blood
D000276:Adjuvants, Immunologic; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D001224:Aspartic Acid; D003687:Dehydroepiandrosterone; D044943:Fatty Acid Desaturases; D042964:Acyl-CoA Dehydrogenase; D002118:Calcium